Inspire Medical Systems Sets Q4/FY23 Earnings Call for Feb 20
Ticker: INSP · Form: 8-K · Filed: Feb 6, 2024 · CIK: 1609550
| Field | Detail |
|---|---|
| Company | Inspire Medical Systems, INC. (INSP) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, conference-call
TL;DR
**INSP earnings call set for Feb 20 after market close; expect volatility.**
AI Summary
Inspire Medical Systems, Inc. filed an 8-K on February 6, 2024, to announce the date of its upcoming earnings call. The company will release its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024, after market close, followed by a conference call at 4:30 PM ET. This matters to investors because it provides a specific date to anticipate key financial performance metrics, which could significantly impact the stock price.
Why It Matters
This filing sets the expectation for when investors will receive crucial financial updates, allowing them to prepare for potential stock volatility based on the reported results.
Risk Assessment
Risk Level: low — This filing is purely administrative, announcing an upcoming event, and does not contain any immediate financial risks or changes.
Analyst Insight
A smart investor would mark February 20, 2024, on their calendar and prepare to analyze the Q4 and full year 2023 financial results for Inspire Medical Systems, Inc. to inform future investment decisions.
Key Players & Entities
- Inspire Medical Systems, Inc. (company) — the registrant filing the 8-K
- February 6, 2024 (date) — date of earliest event reported
- February 20, 2024 (date) — date of Q4 and full year 2023 financial results release and conference call
- 4:30 PM ET (time) — start time of the conference call
- INSP (company) — trading symbol for Common Stock
- New York Stock Exchange (company) — exchange where Common Stock is registered
Forward-Looking Statements
- Inspire Medical Systems, Inc.'s stock (INSP) will experience increased trading volume and potential price volatility around February 20, 2024. (Inspire Medical Systems, Inc.) — high confidence, target: 2024-02-20
FAQ
What is the primary purpose of this 8-K filing by Inspire Medical Systems, Inc.?
The primary purpose of this 8-K filing, dated February 6, 2024, is to announce the date and time for the release of Inspire Medical Systems, Inc.'s fourth quarter and full year 2023 financial results, and the subsequent conference call.
When will Inspire Medical Systems, Inc. release its Q4 and full year 2023 financial results?
Inspire Medical Systems, Inc. will release its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024, after the market closes.
What time is the conference call scheduled for after the earnings release?
The conference call to discuss the financial results is scheduled for 4:30 PM Eastern Time on Tuesday, February 20, 2024.
What is the trading symbol and exchange for Inspire Medical Systems, Inc.'s common stock?
The trading symbol for Inspire Medical Systems, Inc.'s Common Stock is INSP, and it is registered on the New York Stock Exchange.
Under which items of Form 8-K was this report filed?
This report was filed under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 9.2 · Accepted 2024-02-06 16:08:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share INSP New York Stock
Filing Documents
- insp-20240206.htm (8-K) — 29KB
- insp2023-q4pressreleaseex9.htm (EX-99.1) — 104KB
- q42023presentation-xfina.htm (EX-99.2) — 42KB
- inspirelogo.jpg (GRAPHIC) — 14KB
- q42023presentation-xfina001.jpg (GRAPHIC) — 35KB
- q42023presentation-xfina002.jpg (GRAPHIC) — 281KB
- q42023presentation-xfina003.jpg (GRAPHIC) — 222KB
- q42023presentation-xfina004.jpg (GRAPHIC) — 154KB
- q42023presentation-xfina005.jpg (GRAPHIC) — 146KB
- q42023presentation-xfina006.jpg (GRAPHIC) — 117KB
- q42023presentation-xfina007.jpg (GRAPHIC) — 114KB
- q42023presentation-xfina008.jpg (GRAPHIC) — 183KB
- q42023presentation-xfina009.jpg (GRAPHIC) — 107KB
- q42023presentation-xfina010.jpg (GRAPHIC) — 105KB
- q42023presentation-xfina011.jpg (GRAPHIC) — 114KB
- q42023presentation-xfina012.jpg (GRAPHIC) — 120KB
- q42023presentation-xfina013.jpg (GRAPHIC) — 102KB
- q42023presentation-xfina014.jpg (GRAPHIC) — 95KB
- q42023presentation-xfina015.jpg (GRAPHIC) — 83KB
- q42023presentation-xfina016.jpg (GRAPHIC) — 106KB
- q42023presentation-xfina017.jpg (GRAPHIC) — 87KB
- q42023presentation-xfina018.jpg (GRAPHIC) — 116KB
- q42023presentation-xfina019.jpg (GRAPHIC) — 94KB
- q42023presentation-xfina020.jpg (GRAPHIC) — 55KB
- q42023presentation-xfina021.jpg (GRAPHIC) — 25KB
- q42023presentation-xfina022.jpg (GRAPHIC) — 128KB
- q42023presentation-xfina023.jpg (GRAPHIC) — 92KB
- q42023presentation-xfina024.jpg (GRAPHIC) — 120KB
- q42023presentation-xfina025.jpg (GRAPHIC) — 35KB
- q42023presentation-xfina026.jpg (GRAPHIC) — 89KB
- q42023presentation-xfina027.jpg (GRAPHIC) — 140KB
- q42023presentation-xfina028.jpg (GRAPHIC) — 171KB
- q42023presentation-xfina029.jpg (GRAPHIC) — 28KB
- q42023presentation-xfina030.jpg (GRAPHIC) — 65KB
- q42023presentation-xfina031.jpg (GRAPHIC) — 73KB
- q42023presentation-xfina032.jpg (GRAPHIC) — 145KB
- q42023presentation-xfina033.jpg (GRAPHIC) — 165KB
- q42023presentation-xfina034.jpg (GRAPHIC) — 105KB
- 0001609550-24-000013.txt ( ) — 5613KB
- insp-20240206.xsd (EX-101.SCH) — 2KB
- insp-20240206_lab.xml (EX-101.LAB) — 24KB
- insp-20240206_pre.xml (EX-101.PRE) — 13KB
- insp-20240206_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 6, 2024, Inspire Medical Systems, Inc. (the "Company") issued a press release announcing its financial results for the quarter and full year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. In February and March of 2024, the Company will be participating in various meetings with investors and analysts, and a copy of the Company's presentation materials being used at these meetings is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company's website at https://investors.inspiresleep.com. The information in each of Item 2.02 and Item 7.01 of this Current Report on Form 8-K and in the press release attached as Exhibit 99.1 and the presentation attached as Exhibit 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Inspire Medical Systems, Inc., dated Febru ary 6 , 2024. 99.2 Inspire Medical Systems, Inc. Presentation, February 2024 . 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSPIRE MEDICAL SYSTEMS, INC. Date: February 6, 2024 By: /s/ Richard J. Buchholz Richard J. Buchholz Chief Financial Officer 3